Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
Adeno-associated viral gene therapy has shown promise for the treatment of inherited and degenerative diseases in a variety of animal models. Some of the most dramatic results have been obtained in the field of ocular gene therapy, where efficacy has been tremendous in inherited and acquired retinal disorders. For the promise of this approach to be realized it will be necessary to create vectors capable of pharmacologic or physiologic regulation of the transgene. We describe in this paper a dimerizer-inducible viral expression system that is able to reproducibly drive expression of the reporter gene erythropoietin in the eyes of nonhuman primates over a period of 2.5 years. The expression profiles were characterized by minimal basal expression in the absence of inducer and dose-responsive maximal expression in the presence of inducer drug.
Adeno-associated viral gene therapy has shown promise for the treatment of inherited and degenerative diseases in a variety of animal models. Some of the most dramatic results have been obtained in the field of ocular gene therapy, where efficacy has been tremendous in inherited and acquired retinal disorders. For the promise of this approach to be realized it will be necessary to create vectors capable of pharmacologic or physiologic regulation of the transgene. We describe in this paper a dimerizer-inducible viral expression system that is able to reproducibly drive expression of the reporter gene erythropoietin in the eyes of nonhuman primates over a period of 2.5 years. The expression profiles were characterized by minimal basal expression in the absence of inducer and dose-responsive maximal expression in the presence of inducer drug.
Since ancient times, unethical athletes have attempted to gain an unfair competitive advantage through the use of doping substances. A list of doping substances and methods banned in sports is published yearly by the World Anti-Doping Agency (WADA). A substance or method might be included in the List if it fulfills at least two of the following criteria: enhances sports performance; represents a risk to the athlete's health; or violates the spirit of sports. This list, constantly updated to reflect new developments in the pharmaceutical industry as well as doping trends, enumerates the drug types and methods prohibited in and out of competition. Among the substances included are steroidal and peptide hormones and their modulators, stimulants, glucocorticosteroids, beta2-agonists, diuretics and masking agents, narcotics, and cannabinoids. Blood doping, tampering, infusions, and gene doping are examples of prohibited methods indicated on the List. From all these, hormones constitute by far the highest number of adverse analytical findings reported by antidoping laboratories. Although to date most are due to anabolic steroids, the advent of molecular biology techniques has made recombinant peptide hormones readily available. These substances are gradually changing the landscape of doping trends. Peptide hormones like erythropoietin (EPO), human growth hormone (hGH), insulin, and insulin-like growth factor I (IGF-I) are presumed to be widely abused for performance enhancement. Furthermore, as there is a paucity of techniques suitable for their detection, peptide hormones are all the more attractive to dishonest athletes. This article will overview the use of hormones as doping substances in sports, focusing mainly on peptide hormones as they represent a pressing challenge to the current fight against doping. Hormones and hormones modulators being developed by the pharmaceutical industry, which could emerge as new doping substances, are also discussed.
Юлія Труфанова, кандидат юридичних наук, ст. викладач кафедри цивільного права і процесу Тернопільського національного економічного університету ОКРЕМІ ПИТАННЯ ПРИПИНЕННЯ ДОГОВОРУ НАЙМУ У ЗВ'ЯЗКУ З ЛІКВІДАЦІЄЮ ЮРИДИЧНОЇ ОСОБИ В ПРОЦЕСІ БАНКРУТСТВА Розкрито особливості припинення договору найму у зв'язку з ліквідацією юридичної особи в процесі банкрутства. З'ясовано, що відкриття ліквідаційної процедури не припиняє договору найму. Підтримана наукова позиція, що договір найму припиняється з моменту внесення до ЄДР запису про припинення юридичної особи. Ключові слова: найм, припинення договору найму, відмова від договору найму (оренди), ліквідаційна процедура, банкрутство. Труфанова Ю. Отдельные вопросы прекращения договора найма в связи с ликвидацией юридического лица в процессе банкротства.Раскрыты особенности прекращения договора найма в связи с ликвидацией юридического лица. Выяснено, что открытие ликвидационной процедуры не прекращает договора найма. Поддержана научная позиция, что договор найма прекращается с момента внесения в ЕГР записи о прекращении юридического лица.Ключевые слова: найм, прекращения договора найма, отказ от договора найма, ликвидационная процедура, банкротство. Trufanova Yu. Specific issues in terminating the lease agreement due to the liquidation of a legal entity as part of the bankruptcy processThe peculiarities of terminating the lease (rent) agreement in connection with the liquidation of a legal entity are disсussed. It was clarified that the start of a liquidation procedure does not terminate a lease (rent) agreement. The scientific opinion is maintained, that the lease (rent) agreement is terminated from the moment the termination of the legal entity is entered into the USR.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.